217 Atypical pseudoprogression in non-small cell lung cancer treated with pembrolizumab.

Pseudoprogression is a phenomenon associated with immune checkpoint inhibitors (ICIs). It is defined radiologically as an initial increase in tumour size or new lesions, followed by a decrease in tumour burden. Delayed pseudoprogression, seen after an initial response to ICI, is more rarely seen. Whilst rare cases of delayed pseudoprogression in lung cancer have previously been reported, delayed pseudoprogression followed by prolonged stable disease in the absence of further treatment has not been previously documented.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Case Reports Source Type: research